Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America
The Clinics: Internal Medicine Series

Coordinators: Castillo Jorge J, Kapoor Prashant, Sarosiek Shayna

Language: English
Cover of the book Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America

Subjects for Waldenström Macroglobulinemia, An Issue of...

107.08 €

In Print (Delivery period: 14 days).

Add to cartAdd to cart
Publication date:
240 p. · 15x22.8 cm · Hardback
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
  • Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more. 

  • Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice. 

  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. 

Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia Future Directions in the Frontline Management of Waldenström Macroglobulinemia The Management of Relapsed or Refractory Waldenström's Macroglobulinemia Novel Agents in Waldenström Macroglobulinemia Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies Evaluation and Management of Bing-Neel Syndrome Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia Management of Waldenström Macroglobulinemia in Limited-Resource Settings